Tag: Phase
-
DP WORLD REAFFIRMS LONG-TERM PARTNERSHIP WITH INDIA AS EXECUTIVE CHAIRMAN H.E. ESSA KAZIM MAKES FIRST VISIT
Executive Chairman H.E. Essa Kazim, Group CEO Mr. Yuvraj Narayan and members of DP World’s Global Board of Directors engage with JNPA leadership to explore opportunities for deeper collaboration and future investment.Inauguration of Phase 2 of Nhava Sheva Business Park adds one million square feet o…
-
IBM Advances to Stage C of DARPA Quantum Benchmarking Initiative
IBM moves to third phase of DARPA’s rigorous evaluation of approaches to building a fault-tolerant quantum computerYORKTOWN HEIGHTS, N.Y., Oct. 7, 2026 /PRNewswire/ — IBM (NYSE: IBM) today announced it has been selected for Stage C, the third phase of the Quantum Benchmarking Initiative (QBI) led b…
-
izmo Microsystems and IIT Madras Enter Phase II of ₹99.94 Crore MeitY-Sanctioned Silicon Photonics Program
Five-year CPPICS SPECTRA program targets 1.6 Tbps optical transceivers, co-packaged optics, quantum communications and photonic AIBENGALURU, India, Oct. 7, 2026 /PRNewswire/ — izmo Limited (NSE: IZMO) (BSE: 532341) today announced that its semiconductor subsidiary, izmo Microsystems Pvt. Ltd., has …
-
Gas Liquids Engineering Completes Detailed Engineering for TAQA North's Ferrier Gas Plant
CALGARY, AB, Oct. 5, 2026 /PRNewswire/ — Gas Liquids Engineering Ltd. (GLE) is pleased to announce the successful completion of its detailed engineering Issued for Construction (IFC) scope for TAQA North Ltd.’s new Ferrier Gas Plant in west-central Alberta. The facility is currently under construct…
-
CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases
Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits sharedMELBOURNE, Australia and BASEL, Switzerland, Oct. 4, 2026 /PRNewswire/ — CSL and Alentis Therapeutics today announced they have entered into an exclusive global collaborati…
-
Emerald Clinical Trials Appoints Michael Stibilj as Chief Executive Officer to Lead Next Phase of Global Growth
SINGAPORE, Oct. 1, 2026 /PRNewswire/ — Emerald Clinical Trials, a leading global clinical research organization anchored in Asia-Pacific, today announced the appointment of Michael Stibilj as Chief Executive Officer, effective 1 October 2026. The appointment marks the beginning of the company’s nex…
-
Piramal Pharma Solutions and NP2 to Complete Cyclophosphamide Development Phase Next Month
Piramal and NP2 are set to complete the drug development phase of the generic cancer drug cyclophosphamide this October. The development and manufacturing activities are being conducted at Piramal’s dedicated sterile injectable facility in Lexington, Kentucky. This partnership addresses ongoing cycl…
-
Hylenr Completes Phase 1 LCF Reactor Validation at Texas A&M University
Phase 1 testing identified key thermal, noble-gas and material signatures in the Lattice Confinement Fusion (LCF) reactor, with Hylenr now advancing to Phase 2 studies focused on reproducibility, quantitative measurement and commercialization.HYDERABAD, India, Sept. 22, 2026 /PRNewswire/ — Hyderaba…
-
Merry Life Biomedical Advances Global Phase 2 Trial of TML-6, Exploring Cellular Protein Clearance in Early Alzheimer's Disease
Global study brings together nine Taiwan medical centers, seven Swedish sites, and four U.S. centers to evaluate an oral therapy focused on autolysosomal biologyTAIPEI, Sept. 22, 2026 /PRNewswire/ — Merry Life Biomedical today announced the advancement of TML-6, a Taiwan-developed investigational o…
-
Bybit Renews RLUSD Hold & Earn Phase 3 with Zero-Fee Spot Trading and 800,000 XRP Rewards
DUBAI, UAE, Sept. 21, 2026 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, announced Phase 3 of its exclusive RLUSD Hold & Earn program, continuing its dual-token rewards event exclusive on Bybit, powered by Ripple. In addition to bonus APR, Bybit use…
Latest News
About the Author
Your reliable go-to for precise and up-to-date information!
We are dedicated to accuracy, impartiality, and providing news as it unfolds, earning the trust of a wide audience. Keep up with real-time updates on the latest events and trends.